Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Merck_&_Co.
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
hematology rare diseases |
| gptkbp:founded |
2003
|
| gptkbp:founder |
gptkb:Mark_Ptashne
gptkb:John_Knopf gptkb:Tom_Maniatis gptkb:Jack_Lawler |
| gptkbp:headquarters_location |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acceleron Pharma Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:luspatercept
gptkb:sotatercept |
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:XLRN
|
| gptkbp:website |
https://www.acceleronpharma.com/
|
| gptkbp:bfsParent |
gptkb:Acceleron
|
| gptkbp:bfsLayer |
7
|